<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770376</url>
  </required_header>
  <id_info>
    <org_study_id>PANGEA</org_study_id>
    <nct_id>NCT04770376</nct_id>
  </id_info>
  <brief_title>Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab</brief_title>
  <official_title>Prospective Pilot Study for the Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 (ANG1) and Endothelial Internal Tunica Cell Kinase 2 (TiE2) in Patients With Ovarian Cancer Treated With Chemotherapy Associated to bevAcizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale SS Giovanni e Paolo, Venezia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric prospective observational pilot study of translational research in&#xD;
      women with advanced ovarian epithelial cancer. The main purpose of this study is to evaluate&#xD;
      the predictive value of response to treatment with bevacizumab of the circulating levels of&#xD;
      Ang1, Tie2 and VEGF before start of therapy. Secondary aims of the study are to explore the&#xD;
      predictive value of response / resistance to bevacizumab of changes in circulating levels of&#xD;
      Ang1 and Tie2 during treatment and at progression of disease, and to explore the possible&#xD;
      role of circulating VEGF in the modulation of bioavailability of bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relationship between Ang1 and Tie2 values and response to treatment with bevacizumab</measure>
    <time_frame>Before start of chemotherapy</time_frame>
    <description>Relationship between baseline values of Ang1 and Tie2 (considered individually or combined with each other) and response to treatment with bevacizumab (according to RECIST 1.1 criteria).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>relationship between VEGF values and response to treatment with bevacizumab</measure>
    <time_frame>Before start of chemotherapy</time_frame>
    <description>Relationship between baseline values of endogenous VEGF (plasma CTAD levels) and released by platelets during the clot phase (serum levels) and response to treatment with bevacizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relationship between Ang1 and Tie2 levels</measure>
    <time_frame>from baseline (before start of chemotherapy) to 52 weeks from start of chemotherapy or progression of disease</time_frame>
    <description>relationship between Ang1 and Tie2 levels at baseline, during chemotherapy administration and at progression of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anticipation of diagnosis of progression of disease</measure>
    <time_frame>from baseline (before start of chemotherapy) to 52 weeks from start of chemotherapy or progression of disease</time_frame>
    <description>possible anticipation of diagnosis of progression of disease through evaluation of Ang1 and Tie2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF evaluation</measure>
    <time_frame>from baseline (before start of chemotherapy) to 52 weeks from start of chemotherapy or progression of disease</time_frame>
    <description>Evaluation of free VEGF, bevacizumab-bound VEGF and available bevacizumab in relation to clinical response</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab</arm_group_label>
    <description>Quantification of biomarkers will be performed on 100 patients treated with bevacizumab through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)</arm_group_label>
    <description>Quantification of biomarkers will be performed on 50 patients treated with chemotherapy through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.</intervention_name>
    <description>Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.</description>
    <arm_group_label>Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab</arm_group_label>
    <arm_group_label>Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A sample size of 100 patients with advanced epithelial ovarian carcer is expected to be&#xD;
        enrolled in Cohort A (I-II line of chemotherapy associated to bevacizumab) and 50 patients&#xD;
        with advanced epithelial ovarian carcer is expected to be enrolled in Cohort B (I-II line&#xD;
        of chemotherapy, not associated to antiangiogenic drugs)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients â‰¥ 18 years old&#xD;
&#xD;
          -  Diagnosis of histologically confirmed advanced epithelial ovarian carcinoma&#xD;
&#xD;
          -  Women eligible for treatment with a chemotherapy regimen in combination to bevacizumab&#xD;
             (Cohort A)&#xD;
&#xD;
          -  Women eligible for treatment with a chemotherapy regimen not associated to&#xD;
             antiangiogenic drugs (Cohort B)&#xD;
&#xD;
          -  Evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Patient informed consent signature prior to any study-specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancy within 5 years prior to study entry (except for cutaneous&#xD;
             basal cell carcinoma or adequately treated carcinoma in situ of the cervix ).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Zamagni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Zamagni, MD</last_name>
    <phone>051 2144548</phone>
    <phone_ext>+ 39</phone_ext>
    <email>zamagniclaudio.sper@aosp.bo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Zamagni, MD</last_name>
      <phone>051 2144548</phone>
      <phone_ext>+39</phone_ext>
      <email>zamagniclaudio.sper@aosp.bo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gadducci A, Lanfredini N, Sergiampietri C. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. Crit Rev Oncol Hematol. 2015 Oct;96(1):113-28. doi: 10.1016/j.critrevonc.2015.05.009. Epub 2015 Jun 16. Review.</citation>
    <PMID>26126494</PMID>
  </reference>
  <reference>
    <citation>Oliver KE, McGuire WP. Ovarian cancer and antiangiogenic therapy: caveat emptor. J Clin Oncol. 2014 Oct 20;32(30):3353-6. doi: 10.1200/JCO.2014.57.4574. Epub 2014 Sep 15.</citation>
    <PMID>25225422</PMID>
  </reference>
  <reference>
    <citation>Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014 Sep 1;20(17):4549-4558. doi: 10.1158/1078-0432.CCR-13-3248. Epub 2014 Jun 19.</citation>
    <PMID>24947924</PMID>
  </reference>
  <reference>
    <citation>Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC. Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28.</citation>
    <PMID>27351218</PMID>
  </reference>
  <reference>
    <citation>Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C. Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nat Commun. 2018 Nov 7;9(1):4672. doi: 10.1038/s41467-018-07174-1.</citation>
    <PMID>30405103</PMID>
  </reference>
  <reference>
    <citation>Ciccolini J, Serdjebi C, Barbolosi D, Lacarelle B, Barlesi F. Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter. Clin Cancer Res. 2015 Feb 15;21(4):934. doi: 10.1158/1078-0432.CCR-14-2832.</citation>
    <PMID>25691775</PMID>
  </reference>
  <reference>
    <citation>Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, Bocci G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol. 2007 May 1;25(13):1816-8.</citation>
    <PMID>17470880</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Claudio Zamagni MD</investigator_full_name>
    <investigator_title>MD Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>angiopoietin 1</keyword>
  <keyword>tunica interna endothelial cell kinase 2</keyword>
  <keyword>VEGF</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

